Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 33, 2018 - Issue 1
Submit an article Journal homepage
1,071
Views
7
CrossRef citations to date
0
Altmetric
Short Communication

Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors

Minhang XinDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
,
Weiming DuanDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
,
Yifan FengDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
,
Yuan-Yuan HeiDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
,
Hao ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
,
Ying ShenDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
,
Hong-Yi ZhaoDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
,
Shuai MaoDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaView further author information
&
San-Qi ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, P.R. ChinaCorrespondence[email protected]
View further author information
 show all
Pages 651-656 | Received 05 Jan 2018, Accepted 20 Feb 2018, Published online: 14 Mar 2018

References

  • Liu P, Cheng H, Roberts TM, Zhao J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627–44.
  • Ciraolo E, Morello F, Hirsch E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem 2011;18:2674–85.
  • Wei M, Wang X, Song Z, et al. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond. Med Res Rev 2015;35:720–52.
  • Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53:2362–70.
  • Fruman DA, Rommel C. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 2011; 1:562–72.
  • Fruman DA, Cantley LC. Idelalisib-a PI3Kδ inhibitor for B-cell cancers. N Engl J Med 2014;370:1061–2.
  • Norman P. Selective PI3Kδ inhibitors, a review of the patent literature. Expert Opin Ther Pat 2011;21:1773–90.
  • Markham A. Idelalisib: first global approval. Drugs 2014; 74:1701–7.
  • Patel L, Chandrasekhar J, Evarts J, et al. 2,4,6-triaminopyrimidine as a novel hinge binder in a series of PI3Kδ selective inhibitors. J Med Chem 2016;59:3532–48.
  • Patel L, Chandrasekhar J, Evarts J, et al. Discovery of orally efficacious phosphoinositide 3-kinase δ inhibitors with improved metabolic stability. J Med Chem 2016;59:9228–42.
  • de Turiso FG, Hao X, Shin Y, et al. Discovery and in vivo evaluation of the potent and selective PI3Kδ inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro- N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430)). J Med Chem 2016;59:7252–67.
  • Xin M, Hei YY, Zhang H, et al. Discovery of 6-benzamide containing 4-phenylquinazoline derivatives as novel PI3Kδ inhibitors. Lett Drug Des Dis 2017;14:167–74.
  • Furet P, Hebach C, Hogenauer et al. Quinazoline derivatives as PI3K modulators. Patent WO2013027711; 2013.
  • Hoegenauer K, Soldermann N, Stauffer F, et al. Discovery and pharmacological characterization of novel quinazoline-based PI3K delta-selective inhibitors. ACS Med Chem Lett 2016;7:762–7.
  • Hoegenauer K, Soldermann N, Hebach C, et al. Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. Bioorg Med Chem Lett 2016; 26:5657–62.
  • Xin M, Hei YY, Zhang H, et al. Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors. Bioorg Med Chem Lett. 2017;27:1972–7.
  • Xin M, Duan W, Feng Y, et al. Bioorg Med Chem 2018; Available from: https://doi.org/10.1016/j.bmc.2018.03.002.
  • Hei YY, Xin M, Zhang H, et al. Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors. Bioorg Med Chem Lett 2016; 26:4408–13.
  • Zhang H, Xin M, Xie XX, et al. Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. Bioorg Med Chem 2015;23:7765–76.
  • Xin M, Wen J, Tang F, et al. The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors. Bioorg Med Chem Lett 2013; 23:6777–83.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.